Related Experiment Video

Updated: Apr 18, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

BRD4 inhibitor inhibits colorectal cancer growth and metastasis

Yuan Hu1, Jieqiong Zhou2, Fei Ye3

  • 1Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Road, Guangzhou 510515, China. drhuyuan@gmail.com.

International Journal of Molecular Sciences
|January 21, 2015
PubMed

Insights

BRD4 inhibition is a promising therapeutic strategy for colorectal cancer, effectively reducing tumor cells and limiting metastasis. The study highlights BRD4 inhibitor MS417

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Post-translational modifications, specifically lysine acetylation, play a crucial role in cancer development.
  • The multifunctional transcription factor BRD4 is implicated in cancer and represents a potential therapeutic target.
  • BRD4's role in colorectal cancer (CRC) pathogenesis and metastasis requires further investigation.

Purpose of the Study:

  • To investigate the role of BRD4 in colorectal cancer.
  • To evaluate the efficacy of BRD4 inhibition as a therapeutic strategy for CRC.
  • To determine the impact of BRD4 inhibition on colorectal cancer cell proliferation, apoptosis, and metastasis.

Main Methods:

  • Utilized the BRD4 inhibitor MS417 in colorectal cancer cell lines and an animal model.
  • Assessed cancer cell viability, necrosis, and apoptosis following MS417 treatment.
  • Investigated the effect of BRD4 inhibition on epithelial-to-mesenchymal transition (EMT) markers.
  • Performed in vitro migration and invasion assays.
  • Evaluated liver metastasis in a mouse model.

Main Results:

  • BRD4 inhibition by MS417 significantly reduced colorectal cancer cell viability.
  • MS417 treatment affected cancer cells, though not always through direct necrosis or apoptosis.
  • BRD4 inhibition suppressed distal metastasis by regulating key EMT-associated proteins.
  • Demonstrated reduced liver metastasis in vivo and decreased cell migration/invasion in vitro.

Conclusions:

  • BRD4 plays a significant role in colorectal cancer progression and metastasis.
  • BRD4 inhibition is a potent anti-cancer strategy with both tumoricidal and anti-metastatic effects.
  • BRD4 inhibitors like MS417 show potential for clinical application in treating colorectal cancer, particularly for limiting metastasis.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

7.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
738
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.0K